UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 2, 2015

MATINAS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

> 1545 Route 206 South, Suite 302 Bedminster, New Jersey (Address of principal executive offices)

(Commission File Number) 46-3011414 (IRS Employer ID Number)

07921 (Zip Code)

Registrant's telephone number, including area code: (908) 443-1860

Not Applicable (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Matinas BioPharma Holdings, Inc. (the "Company") intends to use the presentation included as Exhibit 99.1 to this report in connection with an investor conference call.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibits 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

Exhibit

Description

99.1 Presentation, as of February 2, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MATINAS BIOPHARMA HOLDINGS, INC.

Date: February 2, 2015

/s/ Roelof Rongen Roelof Rongen, President and Chief Executive Officer

1

OTCQB: MTNB

www.MatinasBioPharma.com



A clinical-stage biopharmaceutical company focused on the development of lipid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions and infectious diseases

BUSINESS UPDATE CONFERENCE CALL



February 2, 2015

Forward Looking Statement

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.



Agenda

- MATINAS BIOPHARMA AND AQUARIUS SYNERGIES AND STRATEGY
 Roelof Rongen, Chief Executive Officer and Co-Founder
- TECHNOLOGY, SCIENTIFIC PARTNERS, MATINAS BIOPHARMA Dr. Raphael J. Mannino, Founder of Aquarius and an Inventor of the Cochleate Bio-delivery Platform Technology
- TRANSACTION SUMMARY AND FINANCIAL OUTLOOK Jerry Jabbour, Chief Business Officer and Co-Founder
- Q&A
- CLOSING REMARKS
 Roelof Rongen



Roelof Rongen


Matinas BioPharma and Aquarius Biotechnologies Synergies and Strategy


MATINAS

Aquarius Biotechnologies Highlights

- Novel lipid-crystal nano-particle cochleate formulation delivery platform
 with opportunity for broad use in anti-infectives
- Proprietary technology platform with broad application expected to drive a robust pipeline in high-value markets and niche, potentially orphan indications
- Lead program for oral administration of Amphotericin B antifungal (MAT2203) expected to enter Phase 2a in 2015 in collaboration with NIH
- Amikacin-based antibiotic potentially fulfilling significant need to treat lifethreatening Gram-negative bacterial infections







MAT9001


A Next Generation Prescription-only Omega-3 Fatty Acid Medication



MAT9001 – Program Achievements

- Promising results with DPA in pre-clinical studies
- Proprietary process for high purity DPA manufacturing, at GMP 10+kg scale
- Development of proprietary soft-gel formulation
- Formation of prominent Scientific Advisory Board
- Filed MAT9001 IND with FDA Q4 2014
- Commenced first human trial for MAT9001 in Canada Q4 2014
- Established robust MAT9001 IP estate:
 - Filed 22 patents across 3 families
 - One U.S. Patent issued Dec. 2014

MATINAS



MAT2203

Amphotericin B Delivered in a Lipid-Crystal Nano-Particle Cochleate Formulation -- Broad-Spectrum Fungicidal Agent --



Cochleate Technology Offers Significant Clinical Improvement Potential

Multi-Organ Protection

 Cochleates act as a shield for the body from otherwise toxic medicinal compounds

Targeted Delivery


Cochleates are carried directly to infection sites

Oral Administration

- Efficacy demonstrated in *in-vivo* animal studies
- Safety demonstrated in Phase 1 human study

MATINAS

Cochleate Targeted Nano-particle Delivery Mitigates the Limitations of Amphotericin B



** Cochleate Platform delivery technology under exclusive license from Rutgers University



Scientific Merit of Cochleate Technology and Clinical Unmet Need has Led to Several NIH Collaborations

- NIH SBIR grants and research contracts towards encochleated Amphotericin B research
- NIH SBIR grants and research contracts toward encochleated Aminoglycoside antibiotics research
 - Amikacin
 - Capreomycin
- Discussion on Clinical Trial Agreement with NIH for Phase 2a clinical study with Amphotericin B in patients is ongoing
- · Other projects under discussion/review
- Continuous stream of legislative initiatives to stimulate antiinfective development
- Significant government funding committed towards development of new anti-infectives



MAT2203 – Recent Significant Advancements

- Completed cryptococcal meningitis mouse studies at NIH with C-Amphotericin B
- Increasing C-Amphotericin B scale to ~800 doses/batch
- Preparing for C-Amphotericin B Phase 2a efficacy trial at NIH – refractory mucocutaneous candidiasis patients



Significant Clinical Need for Fungicidal Agents


Approximately 150,000 potential cases annually in the U.S. alone

		Patient Populations at High Risk for Fungal Infections				
Γ	Invasive Fungal Infections	Hematological Malignancies	Stem Cell Transplants	Solid Organ Transplants		
√ √	Cryptococcal Meningoencephalitis Aspergillosis	✓ Leukemias• ALL• AML	✓ Autologous✓ Allogeneic	✓ Kidney✓ Liver✓ Other		

Potential to Address Orphan Indications

MATINAS

MAT2203 – Development Overview



MAT2501

Amikacin Delivered in a Lipid-Crystal Nano-Particle Cochleate Formulation -- Gram-Negative Aminoglycoside Antibiotic --



MAT2501 – Development Overview

MAT2501

- C-Amikacin

Potential to be first oral administered Amikacin without toxicity or side effects seen with IV


Treating severe and hospital-acquired gramnegative bacterial infections

Potential High-need Indications:

- Cystic Fibrosis pulmonary infections
- · Ventilated patients in ICU or long-term care
- · Hospital acquired urinary track infections

	Discovery	IND Preparation	Early Clinical Development	Phase 3 Development	
MAT2501					
	 Next Steps: ✓ Proof-of-principle testing in animal models showing in vivo efficacy of oral C-Amikacin Formal Pre-Clinical Animal Toxicology Studies Ongoing at NIH IND filing expected late 2015 				

Cochleate Nanoparticle Delivery has Broad Utility with Potential for Orphan Drug Applications





Anti-Infective Companies Garner Significant Value

Company	Lead Program	Indication	Clinical Phase	Share Price*	Market Cap*
Achaogen (AKAO)	plazomicin	Serious bacterial infections due to Multi-Drug-Resistant Enterobacteriaceae	Phase 3	\$11.77	\$209M
Cempra (CEMP)	Solithromycin	Pneumonia (CABP) and urethritis	Phase 3	\$26.30	\$942M
Tetraphase (TTPH)	eravacycline	Serious Multi-Drug-Resistant bacterial infections	Phase 3	\$36.40	\$1.12B
Basilea (BSLN)	Isavuconazole	Antifungal	NDA	\$105.10	\$1.2B
Anacor (ANAC)	Kerydin™	Onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes	Approved	\$36.79	\$1.5B



*As of January 28, 2015

Recently Materialized Transactions Validate Potential in Anti-Infectives Space

	Recent Acquisitions in Antibiotics						
Date	Company	Acquirer	Lead Program	Indication	Stage at time of deal	Deal Total	
12/14	Cubist	Merck	Multiple Anti- infectives	Multiple	Launched/ Approved/ Phase 3	\$9.5B	
11/14	Durata Therapeutics	Actavis	Dalvance	Gram-positive infection	Approved in US	\$675M	
10/14	Optimer Pharma- ceuticals	Cubist	fidaxomicin	Clostridium difficile- associated diarrhea	Launched in US	\$811M	
8/13	Trius Therapeutics	Cubist	Sivextro	Gram-positive infections , MRSA	Phase 3	\$707M	



MAT8800

Fatty Liver Disease Discovery Program



MAT88	300	Treating Fatty Liver Disease			
		• Common 12% of U populatio	• A lead .S. of cirr n • NO API	ling cause	
	Discovery	IND Preparation	Early Clinical Development	Phase 3 Development	
MAT8800					
	 Next Steps: Animal studies ongoing Composition selection or further optimization Upon selection, pre-IND meeting with FDA and IND prepared 				

Experienced Management Team and Board

Strong development and commercialization track record **Roelof Rongen** President and CEO, Director George Bobotas, PhD - Chief Scientific Officer Jerome Jabbour, JD - Chief Business Officer & General Counsel Abdel Fawzy, PhD - EVP Pharmaceutical & Supply Chain Dev. Gary Gaglione, CPA VP Finance, Acting CFO Herbert Conrad, Chairman BOD - Roche, Reliant, Pharmasset, Celldex, Dura, Bone Care James Scibetta, Director - CFO Pacira, Bioenvision/Genzyme, Merrimack Stefano Ferrari, Director - ProSPA, Bioseutica, KD-Pharma Adam Stern, Director - CEO SternAegis Ventures



Prominent Scientific Advisory Board

Dyslipidemia & Cardiovascular Diseases

Christie M. Ballantyne, MD, PhD, FACC, FNLA

 Baylor College of Medicine, Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart and Vascular Center, Lipid Metabolism and Atherosclerosis Clinic at Houston Methodist Hospital

Kevin Maki, PhD, FNLA

 DePaul University, Midwest Center for Metabolic & Cardiovascular Research, Great Lakes Clinical Trials, National Lipid Association's Expert Panel

Anti-Infectives

- J. Carl Craft, MD; Chair
 - Former Chief Scientific Officer for Medicines for Malaria Venture (MMV),
 Former Venture Head at Abbott Laboratories Anti-Infective Development Group

Raphael Mannino, PhD

 Associate Professor of Pathology and Laboratory Medicine at Rutgers University, New Jersey Medical School. Founder, former President, CEO, CSO and EVP of BioDelivery Sciences, Inc.

MATINAS

Raphael Mannino, Ph.D.


Technology, Scientific Partners, Matinas BioPharma



Jerry Jabbour

Transaction Summary and Financial Update





Roelof Rongen

Closing Comments



MTNB Represents a Compelling Investment Opportunity

- Unique and differentiated expertise in lipidomics, lipid chemistry and lipid-based delivery
- Phase 2a and Phase 3 clinical development programs expected to commence in 2015
- Novel technology platform with broad application expected to drive a robust pipeline in high-value markets and niche, potentially orphan indications
- ✓ Strong patent estate across platforms with decades of know-how
- Multiple value-driving catalysts expected over next 12 months
- Experienced management and board with strong development and commercialization track record



OTCQB: MTNB

www.MatinasBioPharma.com



A clinical-stage biopharmaceutical company focused on the development of lipid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions and infectious diseases

BUSINESS UPDATE CONFERENCE CALL

MATINAS

February 2, 2015